Tebra vs Kareo: Which One in 2026?

Pick Tebra if you are buying a current practice platform: chart, claims, patient experience, and growth modules under one commercial name. Pick Kareo if you are defending the clinical and billing line the front office already logs into, and you are not buying a growth suite this quarter. They are not two unrelated vendors. They are two product names a partner will still have to choose between on a quote. A practice that treats the rebrand as a free upgrade, or treats the old login as a different company, will sign the wrong SKU. This page names exactly those two products.

Neither Tebra nor Kareo has a public figure in the vendor store we are allowed to reprint, so this page prints none. Ask for a written quote that covers providers, locations, which modules are in — clinical, billing, patient experience, marketing — clearinghouse and claims volume, EHR data conversion, the BAA, professional services, and how a dual-run month is billed. Module mix and conversion scope are the levers that usually move the number.

How we evaluated

US Tech Automations scored this pair the way a partner has to defend it: by the login the MA opens on Tuesday, not by the logo on the sales slide.

We treated Tebra as the current commercial platform in this pair. We treated Kareo as the clinical and billing product line many small practices still call the chart. Company history is relevant only as far as it changes the quote: which SKUs are still sold, which logins still work, and whether "moving to Tebra" is a conversion or a module expansion.

We treated the chart, claims, scheduling, and patient outreach as separate jobs. A product that is strong on billing is not automatically strong on the growth suite, and the reverse.

We treated HIPAA as a shared-responsibility contract. Request the BAA and the list of covered services in writing. A rebrand does not paper a new addendum by itself.

We printed no vendor prices, no seat fees, and no customer counts. Where a cell would have been a guess, it reads "not published."

We used regulator and statistical-agency numbers for visit volume, health spending, and the access clock, and we dated them.

The comparison is for medical practices, meaning office-based clinics that still live and die by the chart, the claim, and the front desk. Health-system EHR conversions are a different buy.

Who Tebra is actually for

Tebra is the current practice platform in this pair. The buy is a combined story: clinical, billing, and patient-experience modules under one commercial name. Sales will talk about growth. The floor still has to chart, code, and collect.

That is the right shape when the work is "we need a new stack, not a new logo on the old login." It is the right shape when the partner wants scheduling, reminders, and a patient app in the same conversation as claims. It is the right shape when you are leaving a different chart and the quote is a conversion into Tebra, not a rename of Kareo.

Tebra is a poor fit when the practice only needs to keep billing and clinical running and will not staff the growth modules. Paying for a platform story you will not log into is how the front desk stays on the old screens and marketing never launches. It is also a poor fit when the conversion scope is undefined. "We will just switch the name" is not a data-migration plan.

If the practice already knows it is buying a current all-in-one, Tebra is the product in this pair. If the practice mainly needs to keep the clinical and billing line it already runs, skip to Kareo.

Who Kareo is actually for

Kareo is the clinical and billing product line in this pair. Many small practices still open that login for the chart, the superbill, and the claim. The name on the website may say Tebra. The name on the taskbar may still say Kareo. Both can be true on the same Tuesday.

That is the right shape when the work is "do not rip the chart this year." It is the right shape when the biller's muscle memory is the Kareo claim screen and the partner will not fund a conversion. It is the right shape when you are asking which SKUs remain on the clinical and billing line, not which growth suite to add.

Kareo is a poor fit when you need a new practice-growth stack and you are pretending the old clinical login is that stack. Patient-experience modules, if you want them, have to be named on the quote. It is also a poor fit when the vendor will only quote Tebra and you have not asked what happens to the Kareo login, the historical claims, and the encounter archive.

If the practice already knows it is staying on the clinical and billing line, Kareo is the product in this pair. If the practice is buying the current platform on purpose, stay with Tebra.

Chart and billing jobs

Read the table as a job map. "Native" means the product is sold to do that job. "Confirm" means ask which SKU still carries it. "not published" means we will not guess.

Source: product shape from public Tebra and Kareo materials reviewed 2026-09-06. Price cells are not published.

Visit volume is why the login still matters. 85.2% of adults saw a clinician in 2024. Physician office visits: 1.0 billion in 2019. Those visits still have to be charted and billed, whatever the logo says.

Source: CDC NCHS FastStats, physician office visits, last reviewed 9 Jan 2026.

Spending context is why a partner will ask whether this is an EHR conversion or a marketing add-on. Physician and clinical services: $1,109.7 billion in 2024. Claims sit on that line. Growth modules sit next to it. They are still different lines on the quote.

Source: CMS NHE Fact Sheet, page last modified 24 Jun 2026.

Encounters, claims, and messages can all sit in a designated record set. according to the eCFR, the covered entity must act on a request for access no later than 30 days after receipt of the request. A rebrand does not pause that clock.

Source: eCFR 45 CFR 164.524, current as of 3 Sep 2026.

Pros and cons

Tebra

Pros. The product is the current catalog. Clinical, billing, and patient-experience modules can be quoted together. A practice that is leaving a different chart can buy a conversion into one commercial name. Scheduling and outreach can sit next to claims if those SKUs are on the page. One vendor conversation can cover the floor and the growth suite.

Cons. A platform story is not a conversion plan. If the floor still lives in Kareo screens, you have not moved. Public list price is not printed here. Module mix will hide cost until you name clinical, billing, and growth separately. If you only need the chart and the claim, buying the full story is how unused logins accumulate. Historical encounters still have to be producible after the name on the door changes.

Kareo

Pros. The product is the clinical and billing line the floor may already know. Billers keep muscle memory. A partner who will not fund a conversion can still ask which SKUs remain supported. Chart and claim are the jobs this name was sold to do. You can keep the growth conversation off the table this quarter.

Cons. The website may no longer sell this name the way the taskbar still shows it. Confirm support, BAA, and what happens to the login. Patient-experience modules do not silently appear. List price is not published here. If you need a new all-in-one, staying on Kareo because the logo is familiar is how you delay a conversion you already decided to do. If the vendor will only quote Tebra, you still have to map the old screens, the archive, and the claim history.

Switching

The invoice is the smallest part of the switch, and this page will not invent that invoice. Moving from Kareo to Tebra, or quoting Tebra while the floor stays on Kareo, is a conversion and module problem: encounters, claims, schedules, patient lists, BAA, retraining. None of those calendars were published as a vendor figure we can reprint.

Name the move. "Rebrand" is not a move. "Module expansion" is a move. "Chart conversion from a different vendor into Tebra" is a different move. Write which one you are doing on the first page of the quote. If sales cannot tell you which one it is, stop.

Data. Encounters, problem lists, medications, claims, ERA history, schedules, and patient communications all have to land somewhere. Ask for the conversion map. Ask what stays in an archive login. Ask how a patient access request is filled during the dual-run. The patient intake guide is the companion read if the intake packet is the first object that has to move without an EHR API.

Retraining. Providers, MAs, billers, and front desk do not take the same class. If the screens do not change, do not send them to a conversion class. If the screens do change, do not skip the biller. The healthcare automation guide is the companion read if the real question is which workflows sit around the chart, not which logo is on it. Outreach that is not the EHR belongs with healthcare marketing automation so you do not buy a growth module you will not operate.

BAA. Re-paper. A new commercial name is a reason to ask for the covered-SKU list again, not a reason to assume last year's addendum still matches the modules you just added.

Dual-run. Keep the old login reachable until claims, encounters, and access requests look normal. Do not cancel on the cutover morning. Ask how the overlap is billed. The cash cost is not published here.

Source: switching cells are qualitative or not published. No vendor price or duration is printed.

When intake packets should leave a PDF pile and land as a structured record before the chart is even open, US Tech Automations can sit on that handoff — pull the form, extract the fields, and open a missing-item queue — without pretending to be Tebra or Kareo.

When a claim denial should become a coded follow-up instead of an inbox pile, US Tech Automations can own that workflow step, including the data-extraction agent that flags the reason code before a biller re-keys the claim.

Verdict

Pick Tebra if the decision you are defending is "buy the current practice platform on purpose." You want clinical, billing, and named patient-experience modules on one quote. You will still map the conversion. You will still re-paper the BAA. You will still not treat a logo change as a go-live.

Pick Kareo if the decision you are defending is "keep the clinical and billing line the floor already runs." You will confirm that login is still supported. You will not assume growth modules ride along. You will still ask what happens to the archive when the website only says Tebra.

Do not pick Tebra as a silent rename of a Kareo login you are not converting. Do not pick Kareo as a silent substitute for a platform conversion you have already decided to do. If the practice needs both the old chart path and the new growth modules, name both SKUs on the quote. This vs page will not invent a third product to hold the other job.

according to CDC, 85.2% of adults had a visit with a doctor or other health care professional in 2024. Those visits still have to be charted under whichever login you keep.

according to CDC, physician offices recorded 1.0 billion visits, or 320.7 visits per 100 persons, in the 2019 NAMCS summary. Volume is why a half-finished conversion is an operations failure, not a branding exercise.

according to CMS, national health expenditure grew 7.2% to $5.3 trillion in 2024, or $15,474 per person.

according to CMS, physician and clinical services expenditures grew 8.1% to $1,109.7 billion in 2024. Claims sit on that line. Unused growth modules do not collect it.

according to the eCFR, a covered entity may have only one 30-day extension on an access request. A rebrand is not an extra extension.

Quote both names with the same worksheet: providers, locations, modules in or out, conversion scope, archive access, BAA, professional services, and dual-run billing. Bring the answers to pricing if you want the surrounding workflow priced in the same conversation. The homepage for that conversation is US Tech Automations.

FAQs

Which one should a medical practice pick in 2026?

Tebra if you are buying the current practice platform on purpose; Kareo if you are staying on the clinical and billing line the floor already runs. Name the login the MA will open on Tuesday. If you need growth modules and the old chart, name both SKUs on the quote instead of hoping a rebrand is a conversion.

Can a Kareo login be treated as a full Tebra platform?

No. Confirm which modules are actually provisioned. Clinical and billing do not silently become a growth suite. If you want patient-experience SKUs, put them on the quote.

Does choosing Tebra always mean a chart conversion?

No. Sometimes the quote is a module expansion on an existing clinical line. Sometimes it is a conversion from a different chart. Sometimes it is a rename. Write which one it is before you sign. This page will not guess.

What belongs in the quote if neither name has a public figure here?

Ask for providers, locations, modules, claims volume, conversion scope, archive access, the BAA and covered services, professional services, and dual-run billing. If a salesperson quotes a round figure without those lines, send the worksheet back.

How long does cutover take?

A published vendor calendar was not available, so this page does not print one. Plan for the conversion map, retraining, BAA papering, archive export, and a dual-run of the old login. Name an owner for each workstream. Treat "the month it takes" as a project, not a marketing claim.

Do we need a new BAA because the logo changed?

Ask. A new commercial name and a new module list are reasons to re-paper. Do not assume last year's addendum covers a growth SKU you just added. Keep the covered-service list with the privacy officer.

Should billers attend a conversion class if the claim screen does not change?

No. Send the people whose screens change. If only marketing is gaining a module, do not pull the biller off claims week. If the claim screen is retiring, the biller is the first huddle, not the last.

Key Takeaways

• Tebra is the current practice platform in this pair; Kareo is the clinical and billing line the floor may still open.

• Print no list price for either name; quote providers, modules, conversion scope, BAA, and dual-run instead.

• A rebrand is not a conversion; write which move you are actually doing on the quote.

• Visit volume and physician-services spend explain why the chart and the claim still dominate the buy.

• The 30-day access clock still applies to encounters and messages after the logo changes.

• If you need both the old login and new growth modules, name both SKUs; this page will not invent a third product.

• US Tech Automations belongs on the intake and denial handoffs, not as a substitute for the chart vendor.

• Bring the same quote worksheet to both names, then review the surrounding workflow on the pricing page.